TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10710049

Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) pantoprazole (40 mg and 20 mg)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Oral (p.o.) pantoprazole (40 mg and 20 mg)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (i.v.)
Number of subjects: 65
Study: 10436615

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 1485530

Group type: EXPERIMENTAL
Intervention: Raclopride 2‐8 mg twice daily
Number of subjects: 91

Group type: COMPARATOR
Intervention: Haloperidol 5‐20 mg twice daily
Number of subjects: 91
Study: 3545629

Group type: EXPERIMENTAL
Intervention: Omnipaque, 350 mg I/ml
Number of subjects: 38

Group type: COMPARATOR
Intervention: Urografin, 370 mg I/ml
Number of subjects: 38
Study: 30954481

Group type: EXPERIMENTAL
Intervention: Recruitment of cases (women with stillbirth)
Number of subjects: 1269

Group type: COMPARATOR
Intervention: Recruitment of controls (matched for region and gestation)
Number of subjects: 1269

Group type: EXPERIMENTAL
Intervention: Non-participation reasons
Number of subjects: 1269

Group type: EXPERIMENTAL
Intervention: Participant feedback
Number of subjects: 1269

Group type: EXPERIMENTAL
Intervention: Feedback themes
Number of subjects: 1269
Study: 28507219

Group type: EXPERIMENTAL
Intervention: Subcutaneous golimumab (30 mg/m2 of body surface area; maximum: 50 mg/dose) every 4 weeks with weekly methotrexate
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Subcutaneous golimumab
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 27370059

Group type: EXPERIMENTAL
Intervention: Topiramate 50 mg/day
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg/day
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg/day
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 24476416

Group type: EXPERIMENTAL
Intervention: Etanercept (ETA)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 112
Study: 22710953

Group type: EXPERIMENTAL
Intervention: C-LETZ
Number of subjects: 98

Group type: COMPARATOR
Intervention: LLETZ
Number of subjects: 98
Study: 20465033

Group type: EXPERIMENTAL
Intervention: Khat chewing
Number of subjects: 17

Group type: COMPARATOR
Intervention: Non-chewers
Number of subjects: 17
Study: 18322991

Group type: EXPERIMENTAL
Intervention: 40 mg methylprednisolone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 25 mg etanercept
Number of subjects: 25
Study: 15978098

Group type: EXPERIMENTAL
Intervention: Aprotinin (2 x 10(6) KIU bolus followed by 0.5 x 10(6) KIU h(‐1) for 3 h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid (EACA) (10 g over 30 min followed by 5 g over 3 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12679467

Group type: EXPERIMENTAL
Intervention: Recombinant human FSH (r‐hFSH) at doses of 0, 37.5, 75, or 150 IU
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Recombinant human FSH (r‐hFSH) at doses of 37.5 IU and 75 IU
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Recombinant human FSH (r‐hFSH)
Number of subjects: 23
Study: 10568855

Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 92

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 92
Study: 8707193

Group type: EXPERIMENTAL
Intervention: Soy formula with starch (25 infants)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Cow milk-based formula (21 infants)
Number of subjects: 46
Study: 1884058

Group type: EXPERIMENTAL
Intervention: Warfarin 1 mg given daily for one week before and three weeks after surgery
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 148
Study: 31523919

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser treatment (power 12 W, time on 3 ms, PPI 5), two sessions four weeks apart
Number of subjects: 60

Group type: COMPARATOR
Intervention: Topical keratolytic (10% urea)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser treatment
Number of subjects: 60
Study: 30500610

Group type: EXPERIMENTAL
Intervention: Mobile sex workers (2016)
Number of subjects: 2591

Group type: EXPERIMENTAL
Intervention: Mobile sex workers (2013)
Number of subjects: 2591

Group type: EXPERIMENTAL
Intervention: Mobile sex workers
Number of subjects: 2591
Study: 27965261

Group type: EXPERIMENTAL
Intervention: Organ-cultured corneas with endothelial cell density (ECD) measured at day 5 after PK
Number of subjects: 90
Study: 25892544

Group type: EXPERIMENTAL
Intervention: Preventure intervention (two-session coping skills intervention)
Number of subjects: 699

Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 699
Study: 23859414

Group type: EXPERIMENTAL
Intervention: Sauna treatment (30 minutes, 3 days per week for 6 weeks)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Sauna treatment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (education and normal life)
Number of subjects: 26
Study: 21233778

Group type: EXPERIMENTAL
Intervention: HEALTHY intervention (improved school food environment, physical activity and eating educational sessions, social marketing, revised physical education curriculum)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (standard school environment)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intervention group (HEALTHY intervention)
Number of subjects: 42
Study: 19254073

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 17654308

Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg/d)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rofecoxib (25 mg/d)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Aspirin and Rofecoxib
Number of subjects: 10
Study: 16201847

Group type: EXPERIMENTAL
Intervention: Whole flaxseed (FB)
Number of subjects: 0
Study: 12115946

Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide (CP; n = 12)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (PL; n = 11)
Number of subjects: 23
Study: 9927358

Group type: EXPERIMENTAL
Intervention: CPAP treatment for 4 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo treatment for 4 weeks
Number of subjects: 34
Study: 7473117

Group type: EXPERIMENTAL
Intervention: Provisc (n = 32)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Healon (n = 29)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Provisc and Healon
Number of subjects: 61
Study: 2299367

Group type: EXPERIMENTAL
Intervention: Open lung biopsy (OLB) within 8 hours of presentation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Empiric antimicrobial therapy (ET) with trimethoprim‐sulfamethoxazole (TMP‐SMX) and erythromycin for a minimum of 4 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combined randomized and non-randomized groups
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Open lung biopsy (OLB)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Empiric antimicrobial therapy (ET)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Complication rate comparison between patients receiving only empiric antibiotics and all patients having an OLB
Number of subjects: 24
Study: 7014999

Group type: EXPERIMENTAL
Intervention: 0.25-0.5% timolol maleate
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.1% epinephrine hydrochloride
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1% epinephrine
Number of subjects: 40
Study: 30052090

Group type: EXPERIMENTAL
Intervention: Efinaconazole 10% solution once daily for 48 weeks plus 1064 nm Nd: YAG laser (6 treatments every 4 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Efinaconazole 10% solution once daily for 48 weeks
Number of subjects: 30
Study: 27417502

Group type: EXPERIMENTAL
Intervention: Interactive e-Health tool
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Print materials
Number of subjects: 176

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 176
Study: 26114410

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hepatitis A (control)
Number of subjects: 100
Study: 24046309

Group type: EXPERIMENTAL
Intervention: 150 mg oseltamivir twice daily for 5 days
Number of subjects: 155

Group type: COMPARATOR
Intervention: 75 mg oseltamivir twice daily for 5 days
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: 150 mg oseltamivir (subanalysis for influenza B)
Number of subjects: 155

Group type: COMPARATOR
Intervention: 75 mg oseltamivir (subanalysis for influenza B)
Number of subjects: 155
Study: 21829903

Group type: EXPERIMENTAL
Intervention: 12-week group intervention focused on nutrition counseling, lifestyle, physical activity and self-esteem
Number of subjects: 1071
Study: 19788487

Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic gastrostomy (PEG) tube
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-PEG patients
Number of subjects: 20
Study: 17086018

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 15381506

Group type: EXPERIMENTAL
Intervention: Policy of making hip protectors available free of charge to residents, supported by a nurse facilitator over a 72-week period.
Number of subjects: 4137

Group type: COMPARATOR
Intervention: Control group (no hip protectors provided).
Number of subjects: 4137

Group type: EXPERIMENTAL
Intervention: Initial acceptance of hip protectors was 37.2% (508/1,366) with adherence falling to 19.9% (272/1,366) at 72 weeks.
Number of subjects: 4137
Study: 11700183

Group type: EXPERIMENTAL
Intervention: Vaccine (180, 360, and 540 microg doses)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Vaccine (all doses)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Vaccine (360 microg)
Number of subjects: 114
Study: 9812793

Group type: EXPERIMENTAL
Intervention: Bionator headgear combination appliance
Number of subjects: 52

Group type: COMPARATOR
Intervention: Untreated children (control group)
Number of subjects: 52
Study: 8273795

Group type: EXPERIMENTAL
Intervention: 1 g amoxicillin tid intravenously (n = 15)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 500 mg amoxicillin six times daily orally (n = 16)
Number of subjects: 31
Study: 3111339

Group type: EXPERIMENTAL
Intervention: Polydioxanone (PDS)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Prolene
Number of subjects: 284
Study: 29513931

Group type: EXPERIMENTAL
Intervention: AMG 557 210 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 27271554

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (n = 23)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Radiofrequency ablation (n = 18)
Number of subjects: 41
Study: 24767892

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Perceived helpfulness ratings
Number of subjects: 387
Study: 24094085

Group type: EXPERIMENTAL
Intervention: Family-based intervention with 5 interactive booklets about adolescent substance use and risky sexual behavior
Number of subjects: 340
Study: 20803419

Group type: EXPERIMENTAL
Intervention: HD+ colonoscopy with I-Scan functionality
Number of subjects: 220

Group type: COMPARATOR
Intervention: Standard video colonoscopy
Number of subjects: 220
Study: 17440525

Group type: EXPERIMENTAL
Intervention: High-oleic acid, low-trans semiliquid fat
Number of subjects: 44
Study: 15946144

Group type: EXPERIMENTAL
Intervention: rabeprazole 10 mg, amoxicillin 1000 mg and metronidazole 400 mg (RAM-10)
Number of subjects: 120
Study: 11854877

Group type: EXPERIMENTAL
Intervention: 7.5% hypertonic saline (HS)
Number of subjects: 72

Group type: COMPARATOR
Intervention: 0.9% normal saline (NS)
Number of subjects: 72
Study: 10078677

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg midazolam in 15 mg/kg acetaminophen orally
Number of subjects: 86

Group type: COMPARATOR
Intervention: 15 mg/kg acetaminophen orally (placebo)
Number of subjects: 86
Study: 8652038

Group type: EXPERIMENTAL
Intervention: Clorazepate dipotassium (10 mg for < 55 kg; 20 mg for > 55 kg)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Nordiazepam (1 gtt/kg; 5 mg = 24 gtt)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Clorazepate dipotassium (evening and morning)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Clorazepate dipotassium (evening) and Nordiazepam (morning)
Number of subjects: 108
Study: 1977531

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery
Number of subjects: 780

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 780
Study: 6444862

Group type: EXPERIMENTAL
Intervention: Actinac (lotion with chloramphenicol)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Formulation without chloramphenicol
Number of subjects: 37
Study: 31801673

Group type: EXPERIMENTAL
Intervention: Familial high-risk (FHR) group
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (CON) group
Number of subjects: 15
Study: 31780347

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 592

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 592
Study: 29499997

Group type: EXPERIMENTAL
Intervention: WeChat
Number of subjects: 418

Group type: COMPARATOR
Intervention: Leaflet
Number of subjects: 418
Study: 27209439

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (daily capsule containing Lactobacillus acidophilus, L. casei, and Bifidobacterium bifidum for 6 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 24301228

Group type: EXPERIMENTAL
Intervention: Aleph inactivated split influenza vaccine
Number of subjects: 3308

Group type: COMPARATOR
Intervention: Control vaccine (recombinant hepatitis B)
Number of subjects: 3308
Study: 22422823

Group type: EXPERIMENTAL
Intervention: VDCR (Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VDR (Bortezomib, Dexamethasone, and Lenalidomide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VDC (Bortezomib, Dexamethasone, and Cyclophosphamide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VDC-mod (Bortezomib, Dexamethasone, and modified Cyclophosphamide)
Number of subjects: 0
Study: 20002013

Group type: EXPERIMENTAL
Intervention: Rapid enteral feeding advancement at 30 mL/kg/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Slow enteral feeding advancement at 20 mL/kg/day
Number of subjects: 100
Study: 18487613

Group type: EXPERIMENTAL
Intervention: Clomifene citrate plus metformin
Number of subjects: 225

Group type: COMPARATOR
Intervention: Clomifene citrate plus placebo
Number of subjects: 225
Study: 16183794

Group type: EXPERIMENTAL
Intervention: Oral magnesium-containing drugs
Number of subjects: 4290

Group type: COMPARATOR
Intervention: Not applicable (control group without magnesium drugs)
Number of subjects: 4290

Group type: EXPERIMENTAL
Intervention: Increased serum Mg/Ca
Number of subjects: 4290
Study: 14581795

Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented parenteral nutrition (n = 17)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard parenteral nutrition (n = 18)
Number of subjects: 35
Study: 10791177

Group type: EXPERIMENTAL
Intervention: Fecal occult blood testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening methods (general)
Number of subjects: 0
Study: 8997676

Group type: EXPERIMENTAL
Intervention: Electronic probe
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional probe
Number of subjects: 20
Study: 1593867

Group type: EXPERIMENTAL
Intervention: Enriched, warm, leukocyte-depleted blood (Group II)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Enriched, warm, whole blood (Group I)
Number of subjects: 32
Study: 2578880

Group type: EXPERIMENTAL
Intervention: CAP (cyclophosphamide, doxorubicin, and cisplatin)
Number of subjects: 45

Group type: COMPARATOR
Intervention: m-AMSA (amsacrine)
Number of subjects: 45
Study: 30471270

Group type: EXPERIMENTAL
Intervention: Solriamfetol
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 30356217

Group type: EXPERIMENTAL
Intervention: Community organizers who installed solar panels through the programme
Number of subjects: 1400000

Group type: COMPARATOR
Intervention: Community organizers who did not install solar panels through the programme
Number of subjects: 1400000
Study: 26740683

Group type: EXPERIMENTAL
Intervention: Energy Deprivation (ED)
Number of subjects: 21
Study: 25972515

Group type: EXPERIMENTAL
Intervention: Daikenchuto (15.0 g/day, t.i.d)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Daikenchuto
Number of subjects: 336
Study: 22406958

Group type: EXPERIMENTAL
Intervention: Dedicated NIV ventilator
Number of subjects: 15

Group type: COMPARATOR
Intervention: ICU ventilator without NIV algorithm
Number of subjects: 15

Group type: COMPARATOR
Intervention: ICU ventilator with NIV algorithm
Number of subjects: 15
Study: 19619900

Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention
Number of subjects: 104

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 104
Study: 18759642

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 110
Study: 16124431

Group type: EXPERIMENTAL
Intervention: Ivermectin, single dose of 50, 100, 150, or 200 microg/kg bodyweight
Number of subjects: 20

Group type: COMPARATOR
Intervention: Albendazole, 400 mg twice a day for 14 days
Number of subjects: 20
Study: 12869342

Group type: EXPERIMENTAL
Intervention: Hospital-at-home
Number of subjects: 78
Study: 10480630

Group type: EXPERIMENTAL
Intervention: Thalidomide (200 mg/day for 4 weeks)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Zidovudine and lamivudine (ZDV/LMV) for 14 days
Number of subjects: 31
Study: 8916820

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg in 10 ml 0.9% saline
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Propofol (Group PP)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Ondansetron (Group O)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Propofol (Group PI)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Propofol (Group PIP)
Number of subjects: 89
Study: 2064488

Group type: EXPERIMENTAL
Intervention: Intermittent intravenous (IV) injections of morphine sulfate 4 mg every 30 to 60 minutes (phase 1)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) with morphine sulfate 2 mg bolus then 1.0 mg with a 6-minute lockout (phase 1)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Intermittent intravenous (IV) injections of morphine sulfate 8 mg every 30 to 60 minutes (phase 2)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) with morphine sulfate 5 mg bolus then 2.7 mg with a 10-minute lockout (phase 2)
Number of subjects: 47
Study: 6698443

Group type: EXPERIMENTAL
Intervention: High sugar diet (112 g refined sucrose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low sugar diet (16 g refined sucrose)
Number of subjects: 12
Study: 31256656

Group type: EXPERIMENTAL
Intervention: Fructosamine > 293 µmol/l
Number of subjects: 1119

Group type: COMPARATOR
Intervention: HbA1c cut-offs (7% and 7.5%)
Number of subjects: 1119
Study: 30270717

Group type: EXPERIMENTAL
Intervention: ONCE PRO (meal replacement)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Controlled diet
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study: 27056766

Group type: EXPERIMENTAL
Intervention: OCT-guided PCI
Number of subjects: 214

Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 214
Study: 24559020

Group type: EXPERIMENTAL
Intervention: Cold X5 hairlaser device
Number of subjects: 2

Group type: COMPARATOR
Intervention: Sham device (control group)
Number of subjects: 2
Study: 18394612

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg (group A1)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Anastrozole 5 mg (group A5)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Clomiphene citrate 50 mg (group CC50)
Number of subjects: 32
Study: 16358550

Group type: EXPERIMENTAL
Intervention: MCT/LCT fat emulsions
Number of subjects: 30

Group type: COMPARATOR
Intervention: LCT fat emulsions
Number of subjects: 30
Study: 12174335

Group type: EXPERIMENTAL
Intervention: RC-Cornet device
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal exaspiratory valve
Number of subjects: 14
Study: 9220304

Group type: COMPARATOR
Intervention: Standard Cognitive Therapy (SCT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Focused Cognitive Therapy (FCT)
Number of subjects: 40
Study: 8192475

Group type: EXPERIMENTAL
Intervention: 15 mg of vancomycin per kg of body weight before anesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: 15 mg of vancomycin per kg of body weight before anesthesia and a second 7.5‐mg/kg dose at the time of initiation of cardiopulmonary bypass
Number of subjects: 20
Study: 3791247

Group type: EXPERIMENTAL
Intervention: 15 mg AZQ/m2/day, i.v., for 3 consecutive days, every 4 weeks
Number of subjects: 2

Group type: COMPARATOR
Intervention: 200 mg BCNU/m2, i.v., every 8 weeks
Number of subjects: 2
Study: 782704

Group type: EXPERIMENTAL
Intervention: 1 mg digoxin i.v.
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 15
Study: 31484340

Group type: EXPERIMENTAL
Intervention: Adherence to WCRF/AICR recommendations (highest score category)
Number of subjects: 2267

Group type: EXPERIMENTAL
Intervention: Adherence to WCRF/AICR recommendations (lowest score category)
Number of subjects: 2267
Study: 29191845

Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (CGM) used for an average of 5 days/week.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HbA1c values between 8.1 and 8.6% (65-70 mmol/mol).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower HbA1c values.
Number of subjects: 0
Study: 26869288

Group type: EXPERIMENTAL
Intervention: Supervised exercise training (ET) program for 12 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Regular medical treatment (Control)
Number of subjects: 34